Literature DB >> 2591419

Pharmacokinetic and pharmacodynamic modelling of metoprolol in rabbits with liver failure.

A Bortolotti1, D Castelli, D Verotta, M Bonati.   

Abstract

The pharmacokinetic and pharmacodynamic profiles of metoprolol were studied in adult male rabbits given 3.2 mg/kg i.v. before and during liver failure. The partition of metoprolol between blood cells and plasma averaged 1.14 in both conditions. Plasma protein binding, concentration-independent, was 32% and 17% in normal and pathological status, respectively. With normal liver function the terminal elimination half-life for the drug was 0.54-0.96 h, rising to 1.0-2.1 h in liver failure. Differences of the same order were observed for total plasma drug clearance (average 3.7 vs 1.5 1/h/kg), MRT (0.77 vs 1.92 h), AUC (0.9 vs 2.2 mg h/l) and k10 (3.17 vs 1.80 h-1). Liver impairment did not affect the volume of distribution of the central compartment, the steady-state volume of distribution and the other intercompartmental rate constants. Although metoprolol was eliminated in the urine, the amount excreted was low (1.5% of the administered dose) in both conditions. The pharmacokinetic model was extended by an 'effect compartment', which has no influence on the predetermined mass of drug in the body, to analyse the relationship between heart rate fall and changes in metoprolol plasma concentrations. After drug administration, heart rate fell rapidly about 90 beats in both states. The mean unbound plasma concentration producing 50% of this reduction was double during liver failure compared to normal condition (0.03 vs 0.07 mg/l), but the temporal aspects of drug equilibration with site of action were similar.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2591419     DOI: 10.1007/BF03190855

Source DB:  PubMed          Journal:  Eur J Drug Metab Pharmacokinet        ISSN: 0378-7966            Impact factor:   2.441


  23 in total

Review 1.  Metoprolol: a review of its pharmacological properties and therapeutic efficacy in hypertension and angina pectoris.

Authors:  R N Brogden; R C Heel; T M Speight; G S Avery
Journal:  Drugs       Date:  1977-11       Impact factor: 9.546

2.  NL-FIT: a microcomputer program for non-linear fitting.

Authors:  G S Landriani; V Guardabasso; M Rocchetti
Journal:  Comput Programs Biomed       Date:  1983 Feb-Apr

3.  Application of Akaike's information criterion (AIC) in the evaluation of linear pharmacokinetic equations.

Authors:  K Yamaoka; T Nakagawa; T Uno
Journal:  J Pharmacokinet Biopharm       Date:  1978-04

Review 4.  Understanding the dose-effect relationship: clinical application of pharmacokinetic-pharmacodynamic models.

Authors:  N H Holford; L B Sheiner
Journal:  Clin Pharmacokinet       Date:  1981 Nov-Dec       Impact factor: 6.447

5.  Pharmacokinetic studies on the selective beta1-receptor antagonist metoprolol in man.

Authors:  C G Regårdh; K O Borg; R Johansson; G Johnsson; L Palmer
Journal:  J Pharmacokinet Biopharm       Date:  1974-08

6.  Loss of propranolol during ultrafiltration in plasma protein binding studies.

Authors:  D L Parsons; H F Fan
Journal:  Res Commun Chem Pathol Pharmacol       Date:  1986-12

7.  Atenolol determination by high-performance liquid chromatography and fluorescence detection.

Authors:  Y G Yee; P Rubin; T F Blaschke
Journal:  J Chromatogr       Date:  1979-04-01

8.  Simultaneous modeling of pharmacokinetics and pharmacodynamics: application to d-tubocurarine.

Authors:  L B Sheiner; D R Stanski; S Vozeh; R D Miller; J Ham
Journal:  Clin Pharmacol Ther       Date:  1979-03       Impact factor: 6.875

9.  Propranolol pharmacodynamic modeling using unbound and total concentrations in healthy volunteers.

Authors:  R L Lalonde; R J Straka; J A Pieper; M B Bottorff; D M Mirvis
Journal:  J Pharmacokinet Biopharm       Date:  1987-12

Review 10.  Metoprolol. An updated review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy, in hypertension, ischaemic heart disease and related cardiovascular disorders.

Authors:  P Benfield; S P Clissold; R N Brogden
Journal:  Drugs       Date:  1986-05       Impact factor: 9.546

View more
  1 in total

1.  Interspecies scaling and prediction of human clearance: comparison of small- and macro-molecule drugs.

Authors:  Yeamin Huh; David E Smith; Meihau Rose Feng
Journal:  Xenobiotica       Date:  2011-09-05       Impact factor: 1.908

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.